Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Globeflex Capital L P

Globeflex Capital L P grew its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 217.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,596 shares of the company’s stock after purchasing an additional 60,656 shares during the quarter. Globeflex Capital L P owned approximately 0.12% of Kiniksa Pharmaceuticals worth $1,752,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of KNSA. Wellington Management Group LLP acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $1,192,000. JPMorgan Chase & Co. acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $4,997,000. Parkman Healthcare Partners LLC boosted its position in Kiniksa Pharmaceuticals by 16.7% during the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock worth $18,874,000 after acquiring an additional 108,102 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $675,000. Finally, SG Americas Securities LLC acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $355,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at approximately $595,553.60. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 73,423 shares of company stock valued at $1,541,812 in the last ninety days. Corporate insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48. The firm’s fifty day moving average price is $19.95 and its 200 day moving average price is $22.22.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals’s revenue was up 46.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.35 earnings per share. Analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $40.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.